Daehwa Pharmaceutical
Daehwa Pharmaceutical is a South Korea–based pharmaceutical company focused on drug discovery, formulation development and commercial manufacture of finished-dose pharmaceuticals across multiple therapeutic areas. The company emphasizes new drug development (including oral oncology formulations), formulation innovation (e.g., controlled-release and transdermal systems), GMP manufacturing, clinical development (Phase 1–3) and international regulatory submissions. It also maintains certified management systems for compliance, safety and environmental management.
Industries
Nr. of Employees
small (1-50)
Daehwa Pharmaceutical
Seoul, Seoul-t'ukpyolsi, South Korea, Asia
Patents
Pharmaceutical composition for oral administration comprising high concentration taxane
US-11020370-B2
View DetailsPharmaceutical composition for oral administration comprising high concentration taxane
US-10987335-B2
View DetailsPharmaceutical composition for prevention or treatment of cognitive function disorders comprising spinosin
US-9956242-B2
View DetailsComposition for solubilization of paclitaxel and preparation method thereof
US-8075917-B2
View Details
Pharmaceutical composition for oral administration comprising high concentration taxane
US-11020370-B2
View DetailsPharmaceutical composition for oral administration comprising high concentration taxane
US-10987335-B2
View DetailsPharmaceutical composition for prevention or treatment of cognitive function disorders comprising spinosin
US-9956242-B2
View DetailsComposition for solubilization of paclitaxel and preparation method thereof
US-8075917-B2
View DetailsProducts
Finished‑dose pharmaceuticals across therapeutic areas
Commercial tablet, patch, film and liquid products for cardiovascular, endocrine, gastrointestinal, antithrombotic, hypertension and oncology indications.
Oral oncology formulation (oral anticancer product)
Oral chemotherapeutic formulation developed and advanced through clinical trials and regulatory filings in multiple jurisdictions.
Finished‑dose pharmaceuticals across therapeutic areas
Commercial tablet, patch, film and liquid products for cardiovascular, endocrine, gastrointestinal, antithrombotic, hypertension and oncology indications.
Oral oncology formulation (oral anticancer product)
Oral chemotherapeutic formulation developed and advanced through clinical trials and regulatory filings in multiple jurisdictions.
Services
Production and commercial distribution of finished‑dose pharmaceuticals in tablets, oral liquids, patches/adhesives, films and related formats.
Clinical program management, IND preparation and coordination of multi‑phase clinical trials and partner clinical activity.
Production and commercial distribution of finished‑dose pharmaceuticals in tablets, oral liquids, patches/adhesives, films and related formats.
Clinical program management, IND preparation and coordination of multi‑phase clinical trials and partner clinical activity.
Expertise Areas
- Clinical trial management and IND submissions
- Formulation development (oral, controlled‑release, ODF)
- Transdermal drug delivery systems (TDDS)
- GMP pharmaceutical manufacturing
Key Technologies
- Oral controlled‑release formulations
- Orally disintegrating film (ODF) technology
- Transdermal drug delivery systems (TDDS)
- GMP multi‑dosage‑form manufacturing
News & Updates
The company posted its 39th business report; future reports may be updated to DART (regulatory disclosure).
Announcement of acquisition of a patent for controlled drug‑release orally disintegrating film technology.
Announcement that a Chinese partner submitted an IND for a combination trial involving the company's oral oncology formulation.
Company obtained multiple management system certifications (example years and standards listed in corporate history).
History lists approvals and clinical milestones including multi‑country clinical trial approvals, FDA/EMA/foreign interactions and export/marketing authorizations.
The company posted its 39th business report; future reports may be updated to DART (regulatory disclosure).
Announcement of acquisition of a patent for controlled drug‑release orally disintegrating film technology.
Announcement that a Chinese partner submitted an IND for a combination trial involving the company's oral oncology formulation.
Company obtained multiple management system certifications (example years and standards listed in corporate history).
History lists approvals and clinical milestones including multi‑country clinical trial approvals, FDA/EMA/foreign interactions and export/marketing authorizations.